咪喹莫特对伴有高危型人乳头瘤病毒感染的宫颈尖锐湿疣的药物疗效及安全性观察  

Efficacy and safety of imiquimod in cervical condyloma acuminata with high-risk HPV infection

作　　者：谭梅 王建平[2] TAN Mei;WANG Jianping(Western Pharmacy,Enshi Prefecture Elhnic Hospital of Hubei Province,Enshi 445000,Hubei,China;Pharmacologieal Laboratory,Wuhan University,Wuhan 430000,Hubei,China)

机构地区：[1]湖北省恩施州中心医院住院西药房,湖北恩施445000 [2]武汉大学药理实验室,武汉430000

出　　处：《中国性科学》2021年第12期123-126,共4页Chinese Journal of Human Sexuality

基　　金：湖北省卫生计生委指定性项目(WJ2017D0012)。

摘　　要：目的探讨咪喹莫特对伴有高危型人乳头瘤病毒(HPV)感染的宫颈尖锐湿疣的药物疗效及安全性。方法选取2017年1月至2018年10月湖北省恩施州中心医院诊治的58例宫颈尖锐湿疣伴高危型HPV感染患者作为研究对象。所有患者均接受高频电刀治疗,依据随机信封法将其分为对照组和研究组,各29例。对照组治疗后仅采取常规抗感染治疗,研究组则另外给予咪喹莫特治疗,比较两组的临床疗效、用药不良反应发生率,比较两组HPV-DNA病毒载量及病毒转阴率。结果研究组治疗后3个月总有效率、6个月总有效率均高于对照组,差异具有统计学意义(P<0.05);研究组不良反应发生率为3.45%,低于对照组的24.14%,差异具有统计学意义(P<0.05);治疗前及治疗后1个月,两组HPV-DNA病毒载量及病毒转阴率比较,差异无统计学意义(P>0.05);治疗后3个月及6个月,研究组HPV-DNA病毒载量较对照组下降幅度明显,研究组病毒转阴率较对照组升高幅度明显,差异具有统计学意义(P<0.05)。结论对伴有高危型HPV感染的宫颈尖锐湿疣患者给予咪喹莫特治疗的临床效果显著,可有效提升病毒转阴率,且具有一定的用药安全性。Objective To discuss the efficacy and safety of imiquimod in cervical condyloma acuminata with high-risk human papilloma virus(HPV) infection. Methods 58 patients with cervical condyloma acuminatum with high-risk HPV infection treated in Enshi Prefecture Ethnic Hospital of Hubei Province from January 2017 to October 2018 were selected as the research object. All patients were treated with high frequency electric knife, based on the random envelope method divided into control group and the study group, 29 cases each. After that, the control group only adopt routine anti-infection treatment, the study group was also given imiquimod. The clinical efficacy, incidence of adverse drug reactions, HPV-DNA viral load and virus negative conversion rate were compared between the two groups. Results The effective rate of 3 months and 6 months in the study group was higher than those in the control group(P<0.05). The incidence of adverse reactions in the study group was 3.45%, lower than 24.14% in the control group(P<0.05). Before and 1 month after treatment, there was no significant difference in HPV-DNA viral load and virus negative conversion rate between the two groups(P>0.05). At 3 and 6 months after treatment, the viral load of HPV-DNA in the study group decreased significantly compared with the control group, and the viral negative rate in the study group increased significantly compared with the control group, with statistical significance(P<0.05). Conclusions The clinical effect of imiquimod treatment on patients with cervical condyloma acuminatum with high-risk HPV infection is significant, which can effectively improve the virus negative rate, and has a certain drug safety.

关 键 词：咪喹莫特 高危型人乳头瘤病毒感染 宫颈尖锐湿疣 疗效 安全性 

分 类 号：R759[医药卫生—皮肤病学与性病学]